TGFβ1 Immuno-Oncology

Scholar Rock’s novel therapeutics are designed to enhance the ability of the immune system to turn the body’s natural defenses against cancer by selectively targeting supracellular activation of TGFβ1 on the surface of immune cells in the tumor microenvironment and in the tumor stroma. To address the broadest array of cancer types, we have programs that selectively target the function of immunosuppressive regulatory T cells, tumor associated macrophages and other immune cells.

Scholar Rock’s ongoing efforts in immuno-oncology include a successful discovery collaboration with Janssen Biotech (a division of Johnson & Johnson).

“Scholar Rock” is a registered trademark of Scholar Rock, Inc.  |  © 2018 Scholar Rock All Rights Reserved.
Back to Top

The site you are about to visit is maintained by another organization, which is solely responsible for its content. As we cannot control the content or privacy practices of any third-party websites, we encourage you to read the privacy policy of every website you visit.

Continue   Cancel